NEWS
23
2026-07
Good News | Amlodipine Besylate API Officially Approved for Marketing!
Good News | Amlodipine Besylate API Officially Approved for Marketing!
19
2026-07
Set Benchmarks · Embark Anew | Newland Pharma Amoeba Management Phase I Commendation & Training Conference Concludes Successfully
On July 18, Xintiandi Pharma held the Phase I commendation and training activity for the Amoeba Management Project in the multi-functional lecture hall on the third floor of the company. The event was attended by the company’s middle and senior management personnel, all Amoeba leaders, and senior consultants from Bomington Consulting. Centering on phased work summary, outstanding employee recognit
06
2026-07
Meeting in Bangkok, Jointly Forge a New Landscape for Pharmaceuticals Newland Pharma Invites You to CPHI Southeast Asia
Meeting in Bangkok, Jointly Forge a New Landscape for Pharmaceuticals Newland Pharma Invites You to CPHI Southeast Asia
23
2026-06
Good News | Levamlodipine Besylate API Approved!
Good News | Levamlodipine Besylate API Approved!
PRODUCTS
COMPANY PROFILE
We are one of the early domestic manufacturers
engaged in the research, development and production of L-4-Hydroxyphenylglycine and its derivatives. All technical and quality indicators of our products have reached international standards.
CORPORATE CULTURE
The company has established a scientific human
resource management system and a competitive compensation system. Focusing on internal equity, we give full play to the incentive function of salary and benefits.
COMPANY HONOR
The company is a National High-tech Enterprise, a
Key Enterprise under the support of the Ministry of Commerce, a Key Enterprise for the Export of High-tech Products in Henan Province, a Pilot Innovation Enterprise of Henan Province,
Contact Us
Address：East Side, South Weiwu Rd, Changge
Tel：86-374-6105083 6105858
Fax：86-374-6105388
Follow Us
